0000000000714471

AUTHOR

Corrado Toro

showing 2 related works from this author

Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series

2021

(1) Background: Medication-related osteonecrosis of the jaw (MRONJ) is a potential adverse drug reaction of antiresorptive and/or antiangiogenic treatment. MRONJ is mostly diagnosed by anamnestic data, clinical examination and radiological findings, with signs and symptoms often unspecific. On the other hand, oral squamous cell carcinoma (OSCC) is characteristic for its pleomorphic appearance (e.g., ulcer, mucous dehiscence, non-healing post-extractive socket). We report three cases where OSCC mimicked MRONJ lesions. (2) Patients: Three patients undergoing amino-bisphosphonate treatment for osteoporosis presented with areas of intraorally exposed jawbone and unspecific radiological signs co…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryOsteoporosisONJPhysical examinationRK1-715Dehiscencemedicine.diseaseMRONJDermatologyOral Squamous Cell CarcinomaMedication-Related Osteonecrosis of the Jaws MRONJ Case Seriesoral squamous cell carcinomastomatognathic diseasesosteonecrosis of the jawRadiological weaponDentistrymedicinebone exposureIn patientBasal cellOSCCOsteonecrosis of the jawbusinessAdverse drug reaction
researchProduct

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

2023

Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ. Methods This multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients’ data were retrospectively collected from the clinical charts of seven recruiting Italian centres. Results MRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandi…

Bone modifying agentsBreast cancerOsteonecrosis of the jawCancer treatment-induced bone lossONJCTIBLMRONJGeneral DentistryBone modifying agents; Breast cancer; CTIBL; Cancer treatment-induced bone loss; MRONJ; ONJ; Osteonecrosis of the jawBMC Oral Health
researchProduct